Stock 1312 KONTAFARMA CHINA HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kontafarma China Holdings Limited

Equities

1312

KYG8918D1088

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-05-10 am EDT 		5-day change 1st Jan Change
0.037 HKD +5.71% Intraday chart for Kontafarma China Holdings Limited +15.62% +2.78%
May. 02 Active Gains Files Winding-Up Petition Against Kontafarma China's Subsidiary MT
Apr. 19 Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,386 894.2 486.2 273.8 251.5 201.2
Enterprise Value (EV) 1 1,676 1,556 1,076 818.8 699.6 447.4
P/E ratio 41.6 x 24.7 x -1.82 x -18.2 x -6.04 x -6.96 x
Yield - - - - - -
Capitalization / Revenue 0.66 x 0.6 x 0.48 x 0.28 x 0.28 x 0.25 x
EV / Revenue 0.8 x 1.05 x 1.07 x 0.85 x 0.78 x 0.55 x
EV / EBITDA 9.99 x 5.32 x 13.3 x 78.8 x -23.2 x -8.98 x
EV / FCF 86.8 x 17 x 2.17 x 11.1 x -13.4 x 7.67 x
FCF Yield 1.15% 5.88% 46% 9.04% -7.47% 13%
Price to Book 0.99 x 0.63 x 0.4 x 0.23 x 0.23 x 0.19 x
Nbr of stocks (in thousands) 5,588,572 5,588,572 5,588,572 5,588,572 5,588,572 5,588,572
Reference price 2 0.2480 0.1600 0.0870 0.0490 0.0450 0.0360
Announcement Date 4/29/19 5/14/20 4/26/21 4/27/22 4/26/23 4/29/24
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,094 1,482 1,009 961.1 894.1 809.1
EBITDA 1 167.8 292.4 81.11 10.39 -30.21 -49.83
EBIT 1 86.29 216.5 17.54 -47.32 -84.41 -92.32
Operating Margin 4.12% 14.6% 1.74% -4.92% -9.44% -11.41%
Earnings before Tax (EBT) 1 108.9 121.7 -0.297 -0.326 -117.7 -43.92
Net income 1 32.5 36.1 -267.2 -15.05 -41.55 -28.84
Net margin 1.55% 2.44% -26.47% -1.57% -4.65% -3.56%
EPS 2 0.005957 0.006471 -0.0479 -0.002699 -0.007447 -0.005170
Free Cash Flow 1 19.31 91.54 495.4 74 -52.28 58.34
FCF margin 0.92% 6.18% 49.09% 7.7% -5.85% 7.21%
FCF Conversion (EBITDA) 11.51% 31.31% 610.69% 712.24% - -
FCF Conversion (Net income) 59.41% 253.57% - - - -
Dividend per Share - - - - - -
Announcement Date 4/29/19 5/14/20 4/26/21 4/27/22 4/26/23 4/29/24
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 290 662 590 545 448 246
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.73 x 2.263 x 7.277 x 52.46 x -14.83 x -4.94 x
Free Cash Flow 1 19.3 91.5 495 74 -52.3 58.3
ROE (net income / shareholders' equity) 3.81% 3.41% -1.23% -0.34% -8.8% -5.51%
ROA (Net income/ Total Assets) 1.59% 3.69% 0.34% -1.16% -2.25% -3%
Assets 1 2,045 979.7 -79,750 1,298 1,843 961.7
Book Value Per Share 2 0.2500 0.2500 0.2200 0.2100 0.2000 0.1900
Cash Flow per Share 2 0.0200 0.0300 0.0300 0.0300 0.0200 0.0100
Capex 1 59.4 81.1 156 67.2 51.7 23.9
Capex / Sales 2.84% 5.47% 15.45% 6.99% 5.78% 2.96%
Announcement Date 4/29/19 5/14/20 4/26/21 4/27/22 4/26/23 4/29/24
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KONTAFARMA CHINA HOLDINGS LIMITED Stock Kontafarma China Holdings Limited
+2.78% 26.46M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1312 Stock
  4. Financials Kontafarma China Holdings Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW